<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="Publisher" Owner="NLM">
      <PMID Version="1">35560228</PMID>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1528-1167</ISSN>
          <JournalIssue CitedMedium="Internet">
            <PubDate>
              <Year>2022</Year>
              <Month>May</Month>
              <Day>12</Day>
            </PubDate>
          </JournalIssue>
          <Title>Epilepsia</Title>
          <ISOAbbreviation>Epilepsia</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Worth the paper they're printed on? Findings from an independent evaluation of how understandable patient information leaflets for antiseizure medications are.</ArticleTitle>
        <ELocationID EIdType="doi" ValidYN="Y">10.1111/epi.17299</ELocationID>
        <Abstract>
          <AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">The Patient Information Leaflet (PIL) is an authoritative document that all people with epilepsy (PWE) in the European Union receive when prescribed anti-seizure medication (ASM). We undertook the first independent, comprehensive assessment to determine how understandable they are. Regulators state that when patients are asked comprehension questions about them, â‰¥80% should answer correctly. Also recommended PILs have a maximum reading requirement of US Grade 8.</AbstractText>
          <AbstractText Label="METHODS" NlmCategory="METHODS">Study 1: Obtained 140 current ASM PILs written in English. 'Readability' assessed using 4 tests, with and without adjustment for influence of familiar, polysyllabic words. 179 online materials on epilepsy also assessed. Study 2: Two PILs from Study 1 randomly selected (Pregabalin Focus; Inovelon) and shown to 35 people from UK epilepsy population. Their comprehension was assessed. Study 3: To understand whether student population provides accessible alternative population for future examination of ASM PILs, Study 3 was completed. Used same methods as Study 2 but participants were 262 UK university students.</AbstractText>
          <AbstractText Label="RESULTS" NlmCategory="RESULTS">Study 1: No PIL had a reading level of Grade 8. Median was 11. Adjusting for context, the PILs were still at Grade 10.5. PILs for branded ASMs were most readable. PILs were no more readable than (unregulated) online materials. Study 2: Users struggled to comprehend the PILs key messages. The 8 questions asked about pregabalin were typically answered correctly by 54%. For Inovelon it was 62%. Study 3: Most student participants comprehend the PILs key messages. The questions about Inovelon were answered correctly by 90%; for pregabalin it was 86%.</AbstractText>
          <AbstractText Label="SIGNIFICANCE" NlmCategory="CONCLUSIONS">This is the first independent and comprehensive examination of ASM PILs. Found PILs being used fail to meet recommendations and regulatory requirements and risk not being understandable to substantial proportion of users. In finding that people from epilepsy population differ markedly in comprehension of PILs compared to students, study highlights importance of completing user testing with the target population.</AbstractText>
          <CopyrightInformation>This article is protected by copyright. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Noble</LastName>
            <ForeName>Adam J</ForeName>
            <Initials>AJ</Initials>
            <Identifier Source="ORCID">0000-0002-8070-4352</Identifier>
            <AffiliationInfo>
              <Affiliation>Department of Public Health, Policy and Systems, University of Liverpool, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Haddad</LastName>
            <ForeName>Sarah</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychological Sciences, University of Liverpool, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Coleman</LastName>
            <ForeName>Niamh</ForeName>
            <Initials>N</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Psychological Sciences, University of Liverpool, Liverpool, UK.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Marson</LastName>
            <ForeName>Anthony G</ForeName>
            <Initials>AG</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Pharmacology and Therapeutics, University of Liverpool., UK.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2022</Year>
          <Month>05</Month>
          <Day>12</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Epilepsia</MedlineTA>
        <NlmUniqueID>2983306R</NlmUniqueID>
        <ISSNLinking>0013-9580</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Anticonvulsants</Keyword>
        <Keyword MajorTopicYN="N">Comprehension</Keyword>
        <Keyword MajorTopicYN="N">Epilepsy</Keyword>
        <Keyword MajorTopicYN="N">Pamphlets</Keyword>
        <Keyword MajorTopicYN="N">Pregabalin</Keyword>
        <Keyword MajorTopicYN="N">Self-Management</Keyword>
        <Keyword MajorTopicYN="N">rufinamide</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2022</Year>
          <Month>4</Month>
          <Day>21</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2022</Year>
          <Month>3</Month>
          <Day>16</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>10</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>13</Day>
          <Hour>18</Hour>
          <Minute>52</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>14</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>aheadofprint</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">35560228</ArticleId>
        <ArticleId IdType="doi">10.1111/epi.17299</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
